{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 470603074
| IUPAC_name = [(8''R'',9''S'',10''R'',13''S'',14''S'',17''S'')-10,13-Dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[''a'']phenanthren-17-yl] undecanoate
| image = Testosterone undecanoate.svg
| width = 250

<!--Clinical data-->
| pronounce = {{IPAc-en|t|ɛ|ˈ|s|t|ɒ|s|t|ə|r|oʊ|n|_|ə|n|ˈ|d|ɛ|k|ə|n|oʊ|.|eɪ|t}} {{respell|tess|TOSS|tə-rohn ən|DEK|ə-noh-ayt}}
| tradename = 
| pregnancy_category = X ([[United States|USA]]), [[Teratogen]]ic effects
| legal_status = 
| legal_CA = Schedule IV
| legal_US = Schedule III
| routes_of_administration = [[Oral administration|Oral]], [[intramuscular injection]]

<!--Pharmacokinetic data-->
| bioavailability = Oral: 3–7%<br />Intramuscular ~100%{{Citation needed|date=November 2016}}
| metabolism = [[Liver]], [[testis]] and [[prostate]]
| elimination_half-life = 1–12 days{{Citation needed|date=November 2016}}
| excretion = [[Urine]]

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|cas}}
| CAS_number = 5949-44-0
| CAS_supplemental =  
| ATC_prefix = G03
| ATC_suffix = BA03
| PubChem = 65157
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = 
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 58664
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D06087
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = H16A5VCT9C
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 2107067

<!--Chemical data-->
| C=30 | H=48 | O=3
| molecular_weight = 456.70032 g/mol
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C30H48O3/c1-4-5-6-7-8-9-10-11-12-28(32)33-27-16-15-25-24-14-13-22-21-23(31)17-19-29(22,2)26(24)18-20-30(25,27)3/h21,24-27H,4-20H2,1-3H3/t24-,25-,26-,27-,29-,30-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = UDSFVOAUHKGBEK-CNQKSJKFSA-N
| smiles = CCCCCCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C
| synonyms = Aveed, Andriol, Undestor, Nebido, Pantestone, Restandol, Cernos Depot, Nebido-R, Reandron 1000<br />17β-[(1-Oxoundecyl)oxy]-androst-4-en-3-one
}}

'''Testosterone undecanoate''' ([[United States Adopted Name|USAN]], [[British Approved Name|BAN]]) (brand names '''Aveed''', '''Andriol''', '''Androxon''', '''Cernos Depot''', '''Nebido''', '''Panteston''', '''Restandol''', '''Nebido-R''', '''Reandron 1000''', '''Undestor'''), or '''testosterone undecylate''', is an [[androgen]] and [[anabolic steroid]] and a [[testosterone ester]].<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA641|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=641–642}}</ref><ref name="IndexNominum2000">{{cite book|title=Index Nominum 2000: International Drug Directory|url=https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA976|date=January 2000|publisher=Taylor & Francis|isbn=978-3-88763-075-1}}</ref><ref name="MortonHall2012">{{cite book|author1=I.K. Morton|author2=Judith M. Hall|title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA270|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-011-4439-1}}</ref> It is used in [[androgen replacement therapy]] primarily for the treatment of male [[hypogonadism]], and has also been investigated for use as a [[male contraceptive]] or as [[Hormone replacement therapy (female-to-male)|hormone replacement therapy in transgender men]].<ref>{{cite journal|author1=JW Jacobeit|author2=LJ Gooren|author3=HM Schulte|title=Long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals.|journal=[[The Journal of Sexual Medicine]]|date=2007|volume=4|issue=5|pages=1479–84|doi=10.1111/j.1743-6109.2007.00556.x|pmid=17635694}}</ref><ref>{{cite journal|author1=JW Jacobeit|author2=LJ Gooren|author3=HM Schulte|title=Safety aspects of 36 months of administration of long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals|journal=[[European Journal of Endocrinology]]|date=2009|volume=161|issue=5|pages=795–8|doi=10.1530/EJE-09-0412|pmid=19749027}}</ref> Unlike other testosterone esters, testosterone undecanoate is available in both oral and intramuscular formulations.<ref name="Köhn-2003">{{cite journal|first1=Frank-Michael|last1=Köhn|first2=Wolf-Bernhard|last2=Schill|title=A new oral testosterone undecanoate formulation|url=https://link.springer.com/article/10.1007/s00345-003-0372-x|journal=World Journal of Urology|date=November 2003|pages=311–315|volume=21|issue=5|doi=10.1007/s00345-003-0372-x|pmid=14579074}}</ref>

Testosterone undecanoate has a very long [[elimination half-life]] and [[Residence time (fluid dynamics)#Pharmaceutical|mean residence time]] when given as a [[depot injection|depot]] [[intramuscular injection]].<ref name="PayneHardy2007">{{cite book|author1=Anita H. Payne|author2=Matthew P. Hardy|title=The Leydig Cell in Health and Disease|url=https://books.google.com/books?id=x4ttqKIAOg0C&pg=PA423|date=28 October 2007|publisher=Springer Science & Business Media|isbn=978-1-59745-453-7|pages=423–}}</ref> The elimination half-life and mean residence time of testosterone undecanoate are 2.5-fold and 4-fold longer than those of [[testosterone enanthate]] (the values for testosterone enanthate being 4.5 days and 8.5 days, respectively).<ref name="PayneHardy2007" />

Testosterone undecanoate is available in [[Europe]] and Aveed brand testosterone undecanoate was approved for use in the [[United States]] by the [[FDA]] in 2014, after three previous rejections due to safety concerns.<ref name="Lavin2012">{{cite book|author=Norman Lavin|title=Manual of Endocrinology and Metabolism|url=https://books.google.com/books?id=9Zu0MxB8NDYC&pg=PA313|date=28 March 2012|publisher=Lippincott Williams & Wilkins|isbn=978-1-4511-4914-2|pages=313–}}</ref><ref>{{cite web|author1=Miriam E. Tucker|title=FDA Approves Aveed Testosterone Jab, with Restrictions|url=http://www.medscape.com/viewarticle/821632|website=[[Medscape]]|accessdate=December 13, 2016|date=March 7, 2014}}</ref> It is administered at a dosage of 1,000&nbsp;mg every 12 weeks via intramuscular injection.<ref name="BertelloniHiort2010">{{cite book|author1=S. Bertelloni|author2=O. Hiort|title=New Concepts for Human Disorders of Sexual Development|url=https://books.google.com/books?id=CQhaAgAAQBAJ&pg=PA256|date=28 September 2010|publisher=S. Karger AG|isbn=978-3-8055-9569-8|pages=256–}}</ref> In addition to parenteral, an oral formulation of testosterone undecanoate (brand name Andriol) is also available in Europe, but must be taken two or three times a day in combination with food.<ref name="BertelloniHiort2010" /><ref name="Fourcroy2008">{{cite book|author=Jean L. Fourcroy|title=Pharmacology, Doping and Sports: A Scientific Guide for Athletes, Coaches, Physicians, Scientists and Administrators|url=https://books.google.com/books?id=nV3kDPoek5kC&pg=PA25|date=27 October 2008|publisher=Routledge|isbn=978-1-134-08880-5|pages=25–}}</ref>

The Reandron 1000 formulation (Nebido in the United States) contains 1000&nbsp;mg of testosterone undecanoate suspended in [[castor oil]] with [[benzyl benzoate]] for solubilisation and as a [[preservative]], and is administered by [[intramuscular injection]].  As an [[excipient]], benzyl benzoate has been reported as a cause of [[anaphylaxis]] in a case in Australia.<ref>{{cite journal|last1 = Ong|first1 = G. S. Y.|last2 = Somerville|first2 = C. P.|last3 = Jones|first3 = T. W.|last4 = Walsh|first4 = J. P.|year = 2012|volume = 2012|doi = 10.1155/2012/384054|title = Anaphylaxis Triggered by Benzyl Benzoate in a Preparation of Depot Testosterone Undecanoate|url = https://www.hindawi.com/journals/crim/2012/384054/|journal = [[Case Rep Med.]]|id = 384054|pmid = 22272209|pmc = 3261473}}</ref>  Bayer includes this report in information for health professionals and recommends that physicians "should be aware of the potential for serious allergic reactions" to preparations of this type.<ref name = Nebido>{{cite web|title = Nebido Monograph &ndash; Information for Health Care Professionals|url = http://www.nebido.com/en/hcp/product-information/nebido-monograph/index.php|year = 2016 |accessdate = 19 October 2016|publisher = [[Bayer]]}}</ref>  In Australia, reports to ADRAC, which evaluates reports of [[adverse drug reactions]] for the [[Therapeutic Goods Administration]], show several reports of allergic issues since the anaphylaxis case from 2011.

==See also==
* [[Dimethandrolone undecanoate]]
* [[Nandrolone decanoate]]
* [[Nandrolone undecanoate]]
* [[Testosterone buciclate]]

==References==
{{Reflist|2}}

==External links==
* [https://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?mode=&index=249264&view=expanded Testosterone undecanoate] at the US National Library of Medicine [[Medical Subject Headings (MeSH)]]


{{Androgens and antiandrogens}}
{{Androgen receptor modulators}}

[[Category:Androgens and anabolic steroids]]
[[Category:Androstanes]]
[[Category:Contraception for males]]
[[Category:Testosterone esters]]
[[Category:Transgender and medicine]]